Security key
28036F105
Edgewise Therapeutics, Inc. - Common Stock (EWTX)
CUSIP: 28036F105
Q2 2026 13F Holders as of 30 Jun 2026
- Security type / class
- Equity / Common Stock
- Total 13F shares
- 17,874
- Total 13F value
- $71,811
- Share change
- -198
- SEC-reported price per share
- $40.63
- Number of holders
- 3
- Value change
- -$6,009
- Number of buys
- 1
- Number of sells
- 1
- Shares outstanding
- 107,555,564
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q2 2026
Institutions
3
Top holders
3
EWTX full security history
Ownership snapshot
Full 13F holder table
Previous quarter: Q1 2026
Edgewise Therapeutics, Inc. SEC filings
Edgewise Therapeutics, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 28036F105
Recent filing periods:
Ownership snapshot
Top reported holders of EWTX - Edgewise Therapeutics, Inc. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
ORBIMED ADVISORS LLC
Disclosed value leader
ORBIMED ADVISORS LLC
Comparable rows
15/15
Latest evidence
23 Apr 2026
13F
13D/G
3/4/5
Lead comparable stake: 14%
13D/G row: ORBIMED ADVISORS LLC
Showing 1-6 of 15 holder rows.
Quick read
ORBIMED ADVISORS LLC leads the comparable SEC ownership view at 14%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens ORBIMED ADVISORS LLC's linked filing trail.
Comparable ownership
Top 5
ORBIMED ADVISORS LLC
14%
RA CAPITAL MANAGEMENT, L.P.
9.9%
BAKER BROS. ADVISORS LP
6.9%
Paradigm Biocapital Advisors LP
6.2%
BlackRock, Inc.
5.5%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC |
13F
13D/G
3/4/5
Company · Director, 10%+ Owner
|
14%
from 13D/G
|
$488,832,498
15,518,492 shares
|
— | 31 Mar 2026 |
| RA CAPITAL MANAGEMENT, L.P. |
13F
13D/G
Company
|
9.9%
from 13D/G
|
$328,495,766
10,428,437 shares
|
— | 31 Mar 2026 |
| BAKER BROS. ADVISORS LP |
13F
13D/G
Company
|
6.9%
from 13D/G
|
$207,142,110
6,575,940 shares
|
— | 31 Mar 2026 |
| Paradigm Biocapital Advisors LP |
13F
13D/G
Company
|
6.2%
from 13D/G
|
$231,998,697
7,365,038 shares
|
— | 31 Mar 2026 |
| BlackRock, Inc. |
13F
13D/G
Company
|
5.5%
from 13D/G
|
$203,899,220
6,472,991 shares
|
— | 31 Mar 2026 |
| JANUS HENDERSON GROUP PLC |
13D/G
13F
Company
|
5.5%
|
$197,165,481
5,915,556 shares
|
+$31,204,379 | 31 Mar 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q2 2026
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
3
Shares
17,874
Rows available
3
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q2 2026 vs Q1 2026 Across Filers
Q1 2026 holders
212
Q2 2026 holders
3
Holder diff
-209
| Investor | Q1 2026 Shares | Q2 2026 Shares | Share Diff | Share Chg % | Q1 2026 value | Q2 2026 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend